100
Participants
Start Date
March 4, 2024
Primary Completion Date
October 1, 2025
Study Completion Date
December 1, 2025
BYON4228 + Rituximab
"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
RECRUITING
ASST Spedali Civili di Brescia, Brescia
RECRUITING
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo
RECRUITING
Instituto Europeo di Oncologia, Milan
RECRUITING
IRCCS Ospedale San Raffaele, Milan
RECRUITING
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST, Ravenna
RECRUITING
Vrije Universiteit Medisch Centrum, Amsterdam
RECRUITING
Radboud UMC, Nijmegen
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
RECRUITING
Institut Català d'Oncologia, Barcelona
RECRUITING
Centro Integral Oncológico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro, Madrid
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
University Hospitals Plymouth NHS Trust, Plymouth
Lead Sponsor
Byondis B.V.
INDUSTRY